Objective To investigate effect of edaravone on serum inflammatory factors, 6-keto-prostaglandin F1α(6-keto-PGF1α), thromboxane B2, endothelial function and serum copeptin and N-terminal brain natriuretic peptide (NT-proBNP) in patients with acute cerebral infarction.Methods From March 2013 to September 2014, 213 cases of acute cerebral infarction were selected in the hospital and randomly divided into control group (n=101) and observation group (n =112).Control group were given conventional symptomatic treatment, and observation group were given edaravone injection on the basis of control group.The serum inflammatory cytokines, 6-keto-PGF1α, thromboxane B2, endothelial function, serum copeptin, NT-proBNP and nerve function score and activities of daily living ( ADL) score were compared between two groups.Results Serum CRP, IL-8, IL-10 in observation group after treatment were significantly lower than control group (P<0.05).Plasma thromboxane B2 in observation group after treatment was significantly lower than control group (P<0.05).The levels of 6-keto-PGF1αwas significantly higher than control group (P<0.05).Serum copeptin and NT-proBNP levels in observation group after treatment were significantly lower than control group (P<0.05).Plasma ET-1 in observation group after treatment was significantly lower than control group ( P<0.05 ) , and plasma NO was significantly higher than the control ( P<0.05 ).Neurological function in observation group after treatment was significantly lower than control group (P<0.05), and ADL score was significantly higher (P<0.05). Conclusion The preliminary study shows that edaravone in treatment of acute cerebral infarction may be associated with decreasing serum inflammatory cytokines, increasing 6-keto-PGF1αand reducing thromboxane B2, improving endothelial function and reducing serum copeptin and N-terminal natriuretic peptide.

Objective To compare the prognosis of ST elevation acute myocardial infarction(STEMI) of delayed emergency per‐cutaneous coronary intervention(PCI) and elective PCI following the thrombolysis with reteplase ,and to investigate the clinic value of the former solution .Methods One hundred and twenty STEMI patients were reviewed retrospectively and were divided into 2 groups according to PCI .Eighty two cases were divided into emergency group :thrombolysis with reteplase offered within 6h was followed by elective PCI;38 cases were divided into delayed group:PCI was done after 12-24 h after ATEMI′occurring .The clini‐cal features and CTG changes were recorded ,TIMI class of IRA was conducted before and after PCI ,and their prognosis were com‐pared .Results There was no statistical differences in the class of thrombolysis of myocardial infarction(Class 0 -1 ,2 -3) of in‐farction relative artery (IRA)(4 .88% ,95 .12% vs .5 .26% ,94 .74% ) after PCI(P>0 .05) .There was no statistical difference in LVEF ,LVEDVI and LVESVI 3 months after attack between two groups(P>0 .05) .There was statistical difference in the severe cardiac failure and malignancy arrhythmia between two groups(P<0 .05) ,while no statistical difference exist in angina after infarc‐tion as well as cardiac mortality after attack between two groups(P>0 .05) .Conclusion Delayed emergency PCI to remove the ob‐struction in the coronary artery has no significant difference with elective PCI following thrombolysis in the incidence of composite end point events in STEMI .

Objective To investigate impact of rosuvastatin on cardiac function, lipid levels, blood rheology level and endothelial function in patients with coronary heart disease.Methods 149 cases were randomly divided into two groups, the treatment group (n=76) and control group(n=73).Control group with conventional symptomatic treatment, treatment group on the basis of control group combined rosuvastatin treatment.Cardiac function, blood lipid levels, blood rheology changes and endothelial function levels before and after treatment were comparative analysis.Results LVEF significantly increased after treatment than before treatment between two groups (P<0.05), while LVESV, LVEDV after treatment than before treatment were significantly lower ( P<0.05 ) , LVEF in treatment group was significantly higher than control group ( P<0.05 ) , LVESV, LVEDV was significantly lower than that of control group (P<0.05).The two groups of LDL-C, TC, TG after treatment was significantly lower than before treatment (P<0.05), but HDL-C was higher than before treatment(P<0.05).LDL-C, TC, TG in treatment group after treatment was significantly lower than control group (P<0.05), whereas HDL-C after treatment was significantly higher than control group (P<0.05).Fibrinogen, plasma viscosity, whole blood low shear viscosity, whole blood viscosity was lower than that before treatment (P<0.05), which in treatment group was significantly lower than control group (P<0.05).NO, FMD was significantly higher than before treatment (P<0.05), and ET was significantly lower than before treatment (P<0.05).NO, FMD in treatment group was significantly higher than control group (P<0.05), and ET was significantly lower than control group (P<0.05).Conclusion Rosuvastatin can significantly improve cardiac function, improve blood lipid levels, lower levels of blood rheology, improve endothelial function.